Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLF4
REST API REST API
Homo sapiens
KLF4 is differentially expressed in 353 experiments: 155 organism parts: liver, lung, ... (153 more);, 226 disease states: normal, colon carcinoma, ... (224 more);, 129 cell types 454 cell lines 62 compound treatments and 80 other conditions.
Synonyms GKLF, EZF
Orthologs A7YWE2_BOVIN (Bos taurus)   KLF4 (Danio rerio)   Q4H2J1_CIOIN (Ciona intestinalis)   Klf4 (Mus musculus)   Klf4 (Rattus norvegicus)   klf4 (Xenopus laevis)   KLF4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term epidermal cell differentiation, stem cell maintenance, double-stranded DNA binding, regulation of cell proliferation, intracellular, negative regulation of cell proliferation, transcription, DNA-dependent, response to chemical stimulus, epidermis morphogenesis, transcription from RNA polymerase II promoter, transcription factor binding, cell differentiation, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, regulation of cell differentiation, transcription factor complex, negative regulation of protein kinase B signaling cascade, chromatin, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, zinc ion binding, post-embryonic camera-type eye development, negative regulation of ERK1 and ERK2 cascade, negative regulation of smooth muscle cell proliferation, fat cell differentiation, negative regulation of muscle hyperplasia, response to retinoic acid, sequence-specific DNA binding transcription factor activity, phosphatidylinositol 3-kinase regulator activity, RNA polymerase II transcription factor binding, sequence-specific DNA binding transcription factor recruiting transcription factor activity, transcription regulatory region DNA binding, negative regulation of phosphatidylinositol 3-kinase cascade
InterPro Term Znf_C2H2-like, Znf_C2H2
UniProt Accession B7ZBT2, B7ZBT1, Q5T3J6
Search EB-eye ENSG00000136826
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-TABM-125, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
SW480
1
3
E-GEOD-2509, E-MTAB-37, E-GEOD-18005, E-MEXP-1014
PC3
2
E-MEXP-2034, E-GEOD-5258
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-5823, E-GEOD-3529
MOLT4
2
E-MTAB-37, E-MTAB-62
448 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-TABM-34, ... (57 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-MTAB-25, E-GEOD-6740, E-TABM-145
monocyte
1
3
E-GEOD-11755, E-MEXP-583, E-MEXP-2019, E-GEOD-5099
adipocyte
2
E-AFMX-5, E-MTAB-25
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
123 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (69 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-MTAB-62, E-MTAB-57, E-GEOD-3726
gastric carcinoma
3
E-MTAB-37, E-GEOD-2685, E-GEOD-15460
lung adenocarcinoma
3
E-MTAB-37, E-GEOD-2514, E-MEXP-231
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
220 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-4668, E-GEOD-1417, E-GEOD-5741, E-GEOD-5542, ... (38 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
2
E-GEOD-3982, E-TABM-868, E-GEOD-2706
vanadium
1
E-GEOD-2111
camptothecin
1
E-GEOD-1417
Cxcl12
1
E-GEOD-7307
M-CSF
1
E-GEOD-5099
epidermal growth factor
1
E-GEOD-6462
56 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-994, E-GEOD-5372, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-3325, E-MTAB-69, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-10315, E-TABM-440, E-MEXP-1273, E-GEOD-20505, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-1956, E-MEXP-2069, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, E-MEXP-1403 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-21164, E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, ... (6 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM